Gastric Cancer: Epidemiology and Risk Factors

https://doi.org/10.1016/j.gtc.2013.01.003Get rights and content

Section snippets

Key points

  • There is a 10-fold international variation in the occurrence of gastric cancer, with rates in men double those of women.

  • Globally, rates are declining by approximately 2.5% per annum but this is compensated by growth of and aging in the population.

  • Helicobacter pylori infection is the major risk factor for noncardia gastric cancer and is now regarded by some as a necessary cause of such tumors.

  • The best route to control noncardia gastric cancer would be through eradication of H pylori, although

Incidence and Mortality: Worldwide Estimates

GLOBOCAN 20081, 2 provides the most recent figures available for the worldwide cancer burden. Almost 1 million new cases of gastric cancer (988,000 cases; 7.8% of all cancers) were estimated to have occurred globally in 2008, making it the fourth most common malignancy in the world, after cancers of the lung (1.68 million cases; 12.7% of all cancers), breast (1.31; 10.9%), and colorectum (1.24; 9.8%). More than 73% (728,000 cases) of gastric cancer cases occur in Asia, and almost half the

Helicobacter pylori

H pylori is a spiral Gram-negative bacterium that colonizes the stomach. Although most infections are asymptomatic, H pylori is associated with chronic gastritis, peptic ulcer disease, gastric B-cell mucosa-associated lymphoid tissue lymphoma, and gastric adenocarcinoma. It is thought that H pylori was once ubiquitous in the human population, but in many populations its prevalence is declining in successive birth cohorts and it is now rare among children in Western Europe, North America,

Summary

Gastric cancer is one of the major malignancies in the world, although there is significant international variation in its occurrence with rates in the areas of highest incidence being 10 times greater than in areas of lowest incidence. In general, male rates are double the female rates. Those countries where data are available over time show declining incidence rates with an estimated annual percentage change of −2.5% per annum. In terms of absolute numbers, however, the decline in incidence

Acknowledgments

We thank Joannie Lortet-Tieulent for support in providing the figures and Katiuska Veselinovic for preparing the manuscript.

First page preview

First page preview
Click to open first page preview

References (69)

  • J. Ferlay et al.

    Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

    Int J Cancer

    (2010)
  • J. Ferlay et al.

    GLOBOCAN 2008 v2.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. 2010

    (2010)
  • C. de Martel et al.

    The global burden of cancers attributable to infections in the year 2008: a review and synthetic analysis

    Lancet Oncol

    (2012)
  • M.P. Curado et al.
    (2007)
  • D.M. Parkin et al.

    Fifty years of cancer incidence: CI5 I-IX

    Int J Cancer

    (2010)
  • R.J. Schlemper et al.

    Differences in diagnostic criteria for gastric carcinoma between Japanese and western pathologists

    Lancet

    (1997)
  • An international association between Helicobacter pylori infection and gastric cancer. The EUROGAST Study Group

    Lancet

    (1993)
  • J.V. Joossens et al.

    Dietary salt, nitrate and stomach cancer mortality in 24 countries. European Cancer Prevention (ECP) and the INTERSALT Cooperative Research Group

    Int J Epidemiol

    (1996)
  • P. Sipponen et al.

    Delayed rise in incidence of gastric cancer in females results in unique sex ratio (M/F) pattern: etiologic hypothesis

    Gastric Cancer

    (2002)
  • D.M. Parkin et al.

    Estimates of the worldwide frequency of twelve major cancers

    Bull World Health Organ

    (1984)
  • F. Bray et al.

    Global cancer transitions according to the Human Development Index (2008-2030): a population-based study

    Lancet Oncol

    (2012)
  • K.E. McColl et al.

    Aetiology and classification of adenocarcinoma of the gastro-oesophageal junction/cardia

    Gut

    (2010)
  • S.S. Devesa et al.

    Changing patterns in the incidence of esophageal and gastric carcinoma in the United States

    Cancer

    (1998)
  • A.A. Botterweck et al.

    Trends in incidence of adenocarcinoma of the oesophagus and gastric cardia in ten European countries

    Int J Epidemiol

    (2000)
  • W. Haenszel

    Report of the working group on studies of cancer and related diseases in migrant populations

    Int J Cancer

    (1969)
  • A. Kamineni et al.

    The incidence of gastric carcinoma in Asian migrants to the United States and their descendants

    Cancer Causes Control

    (1999)
  • V. Herrera et al.

    Helicobacter pylori and gastric adenocarcinoma

    Clin Microbiol Infect

    (2009)
  • D. Palli et al.

    Family history and risk of stomach cancer in Italy

    Cancer Epidemiol Biomarkers Prev

    (1994)
  • D. Rothenbacher et al.

    Helicobacter pylori among preschool children and their parents: evidence of parent-child transmission

    J Infect Dis

    (1999)
  • IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Schistosomes, liver flukes and Helicobacter pylori

    IARC Monogr Eval Carcinog Risks Hum

    (1994)
  • Proceedings of the IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Biological Agents. A review of human carcinogens

    IARC Monogr Eval Carcinog Risks Hum

    (2012)
  • H. Brenner et al.

    Is Helicobacter pylori infection a necessary condition for noncardia gastric cancer?

    Am J Epidemiol

    (2004)
  • Helicobacter and Cancer Collaborative Group

    Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts

    Gut

    (2001)
  • J. Huang et al.

    Meta-analysis of the relationship between cagA seropositivity and gastric cancer

    Gastroenterology

    (2003)
  • M. Plummer et al.

    Helicobacter pylori cytotoxin-associated genotype and gastric precancerous lesions

    J Natl Cancer Inst

    (2007)
  • C.A. Gonzalez et al.

    Helicobacter pylori cagA and vacA genotypes as predictors of progression of gastric preneoplastic lesions: a long-term follow-up in a high-risk area in Spain

    Am J Gastroenterol

    (2011)
  • A.M. Ekstrom et al.

    Helicobacter pylori in gastric cancer established by CagA immunoblot as a marker of past infection

    Gastroenterology

    (2001)
  • J.H. Siman et al.

    Helicobacter pylori and CagA seropositivity and its association with gastric and oesophageal carcinoma

    Scand J Gastroenterol

    (2007)
  • J.H. Siman et al.

    Association between Helicobacter pylori and gastric carcinoma in the city of Malmo, Sweden. A prospective study

    Scand J Gastroenterol

    (1997)
  • H. Mitchell et al.

    Immunoblotting using multiple antigens is essential to demonstrate the true risk of Helicobacter pylori infection for gastric cancer

    Aliment Pharmacol Ther

    (2008)
  • C.A. Gonzalez et al.

    Helicobacter pylori infection assessed by ELISA and by immunoblot and noncardia gastric cancer risk in a prospective study: the Eurgast-EPIC project

    Ann Oncol

    (2012)
  • B.M. Roesler et al.

    Eradication treatment of helicobacter pylori infection: its importance and possible relationship in preventing the development of gastric cancer

    ISRN Gastroenterol

    (2012)
  • J.L. Ma et al.

    Fifteen-year effects of Helicobacter pylori, garlic, and vitamin treatments on gastric cancer incidence and mortality

    J Natl Cancer Inst

    (2012)
  • N. Uemura et al.

    Effect of Helicobacter pylori eradication on subsequent development of cancer after endoscopic resection of early gastric cancer

    Cancer Epidemiol Biomarkers Prev

    (1997)
  • Cited by (300)

    • Recent update on application of dihydromyricetin in metabolic related diseases

      2022, Biomedicine and Pharmacotherapy
      Citation Excerpt :

      It is worth noting that oxaliplatin (OXA) is the substrate of MRP2, and the addition of DMY can increase the chemical resistance of OXA, inhibit the high expression and promoter activity of MRP2, and thus reduce the proliferation of OXA-resistant colorectal cancer cells [116]. With the optimization of dietary patterns and improvement of hygiene conditions, the incidence of non-cardia cancer has decreased slightly [114], but in the United States and many European countries [134], the incidence of cardia cancer is on the rise, and gastric cancer is still highly prevalent in men and in developing countries [114,135]. P53 gene plays a prominent role in tumor inhibition and can promote the apoptosis of cancer cells in a variety of cancers [136,137].

    View all citing articles on Scopus

    Conflict of Interests: Nil.

    View full text